Taysha Gene Therapies (TSHA): Cantor Fitzgerald Sees an Increased Likelihood of Success for TSHA-102 - Stock Offers 387% Upside Potential

Taysha Gene Therapies (TSHA) reported on May 28 that significant progress has been made in the development of TSHA-102. This is a gene therapy treatment for Rett syndrome. The Phase 1/2 trials, known as REVEAL, were conducted in two parts: Part A focused on dose finding, while Part B aims to evaluate efficacy and safety in an expanded patient group. In February 2025, the company reported that treatment with TSHA-102 was well-tolerated in both low and high doses, with no serious treatment-related side effects or dose-limiting toxicities in pediatric,...